Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

Inclusion Criteria: * Age 18-65, both gender; * Active Ankylosing Spondylitis; * Participants who have been treated with non-steroidal anti-inflammatory drugs(NSAIDs) and still have active disease, or Participants who are intolerant to NSAIDs and stop the drug; * Participants receiving low-dose oral glucocorticoid therapy (≤10mg/d prednisone) should maintain a stable medication regimen for at least 4 weeks before the first dose of this study. Do not adjust the dose during the entire study period except in emergency situations. * Participants receiving other non-prohibited co-drugs should maintain a stable medication regimen for at least 7 days before the first dose of this study; * Understand and voluntarily signed informed consent. Exclusion Criteria: * A history of known or suspected complete spinal rigidity, or clinical and imaging confirmed complete spinal rigidity; * A history of any other autoimmune rheumatic disease; * Any history of joint prosthesis infection, and the prosthesis is still in place; * Participants who are using strong opioid analgesics (such as methadone, hydromorphone, morphine, etc.); * Participants who have been treated with any JAK inhibitors (such as Tofacitinib, Baricitinib, Ruxolitinib, Filgotinib, Upadacitinib, etc.); * Participants who have drug abuse or alcohol dependence; * Participants who have had herpes virus infection in the past month; * Participants who have a history of venous thrombosis (regardless of current treatment); * Any significant clinical and laboratory abnormalities that the investigator believes will affect the safety evaluator； * Participants who cannot be treated and followed up according to the trial protocol; * Any Participant considered by the investigator to be unsuitable to participate in this clinical study